What is Keros Therapeutics, Inc. worth?
With the base-case assumptions below, a discounted cash flow model on Keros Therapeutics, Inc.'s reported free cash flow gives $99.32 per share. The share price was $9.17 on November 9, 2026, 91% below that value.
Inputs from the filings
Three sets of assumptions
| Case | Growth yrs 1-5 | Discount rate | Value per share | Value vs price |
|---|---|---|---|---|
| Bear | 10.0% | 10.0% | $63.04 | +587% |
| Base | 15.0% | 9.0% | $99.32 | +983% |
| Bull | 20.0% | 8.0% | $166.88 | +1,720% |
Sensitivity: base case value per share
| 1.5% | 2.0% | 2.5% | 3.0% | 3.5% | |
|---|---|---|---|---|---|
| 7.0% | $126.79 | $135.35 | $145.82 | $158.91 | $175.73 |
| 8.0% | $106.15 | $111.71 | $118.27 | $126.15 | $135.78 |
| 9.0% | $91.14 | $94.94 | $99.32 | $104.43 | $110.47 |
| 10.0% | $79.75 | $82.45 | $85.52 | $89.01 | $93.05 |
| 11.0% | $70.85 | $72.83 | $75.04 | $77.53 | $80.35 |
Where the presets come from
Base: years 1 to 5 grow at Keros Therapeutics, Inc.'s revenue growth rate over the last 5 fiscal years (89.5% a year), held between -5% and 15%. Years 6 to 10 grow halfway between that and the long-run rate of 2.5%. Future cash is discounted at 9% a year.
Bear: 5 points less growth, 2% long-run growth, 10% discount rate. Bull: 5 points more growth (at most 25%), 3% long-run growth, 8% discount rate.
Value per share = (present value of 10 years of free cash flow + present value of everything after + cash - debt) / diluted shares.
This is a model run on assumptions, not a recommendation or a price target. Small changes in the discount rate or growth move the result a lot, as the table above shows. Change them yourself in the calculator.
Adjust the assumptions
Move the sliders for growth, long-run growth and discount rate, or switch to average free cash flow, and see the value per share change.
Adjust the assumptions